924 resultados para Older Sub-acute ED Presentations


Relevância:

30.00% 30.00%

Publicador:

Resumo:

A Peperomia serpens (Piperaceae) é uma liana herbácea e epifíta popularmente chamada de “carrapatinho’’. Esta planta cresce na Floresta Amazônica de maneira selvagem em diferentes árvores. As folhas são usadas na medicina tradicional brasileira para dor, inflamação e asma. Neste estudo investigaram-se os efeitos do óleo essencial de P.serpens (OEPs) em roedores através de testes para dor e inflamação. A atividade antinociceptiva foi avaliada usando-se modelos nociceptivos químicos (ácido acético e formalina) e térmicos (placa quente) em camundongos, enquanto a atividade antiinflamatória foi avaliada por testes de edema de pata induzidos por carragenina (Cg) e dextrana em ratos, edema de orelha induzido por óleo de cróton, bem como migração celular, rolamento, e adesão induzida por Cg em camundongos. Além disso, a análise fitoquímica do OEPs foi realizada. A composição química do OEPs foi analisada por cromatografia gasosa acoplada a espectrometria de massa. 25 constituintes, representando 89,51% do total do óleo, foram identificados. (E)-Nerolidol (38.0%), ledol (27.1%), α-humulene (11.5%), (E)-caryophyllene (4.0%) and α-eudesmol (2.7%) foram encontrados como principais constituintes. O pré-tratamento oral com o OEPs (62,5- 500mg/kg) reduziu de maneira significante o número de contorções, com um valor de DE50 de 188,8mg/kg que foi ulitizado em todos os testes. Não houve efeito no teste da placa quente mas reduziu o tempo de lambida em ambas as fases do teste de formalina, efeito que não foi significativamente alterado pela naloxona (0,4 mg/kg). OEPs impediu o desenvolvimento do edema induzido por Cg e dextrana em ratos. Em camundongos, o OEPs inibiu o edema induzido por óleo de cróton bem como a migração de leucócitos e neutrófilos, e rolamento e adesão. Estes resultados sugerem que o OEPs possui atividade antinociceptiva periférica sem interação com receptores opióides e atividade antiinflamatória em diferentes modelos de inflamação aguda.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

O paracetamol (PAR) é um dos medicamentos de venda livre mais utilizado em todo o mundo. Entretanto, doses elevadas do PAR produzem toxicidade hepática e/ou renal. No intuito de minimizar a toxicidade do PAR e obter melhor atividade analgésica e anti-inflamatória, um estudo prévio realizou modificações na estrutura química do PAR por modelagem molecular, dando origem ao ortobenzamol (OBZ) – análogo do PAR. Assim, o OBZ foi sintetizado e avaliado em modelos de nocicepção e inflamação em animais. O estudo demonstrou atividade analgésica central do OBZ, com potência superior ao PAR. Além disso, nos testes de inflamação, essa droga apresentou inibição significativa no processo inflamatório. Entretanto, para que o OBZ possa ser considerado uma alternativa terapêutica nova e importante para o tratamento da dor e/ou da inflamação é necessário determinar sua toxicidade. Assim, este estudo objetivou avaliar a toxicidade in vitro e in vivo do OBZ e, compará-la com a do PAR. Para isso, a neurotoxicidade foi avaliada in vitro em culturas primárias de neurônios corticais, através de ensaios de viabilidade celular, determinação dos níveis de glutationa total e reduzida, assim como a possível capacidade neuroprotetora frente ao estresse oxidativo. Foram realizados estudos in vivo em camundongos, iniciados pela determinação da dose efetiva mediana (DE50) do PAR, a fim de compará-la com a do OBZ nos modelos de toxicidade estudados. Determinou-se o estresse oxidativo hepático e cerebral pela análise dos níveis de peroxidação lipídica e nitritos. A possível disfunção hepática e renal foi determinada, por meio da análise dos níveis plasmáticos das enzimas aspartato aminotransferase (AST), de alanina aminotransferase (ALT), gama glutamiltransferase (GGT) e, da creatinina no sangue. Avaliaram-se alterações nos parâmetros clínicos através do hemograma, leucograma e plaquetograma e, realizou-se a determinação da toxicidade aguda. Os resultados obtidos neste estudo demonstraram que o ortobenzamol é mais seguro que o paracetamol. Registrou-se ao ortobenzamol ausência de neurotoxicidade, menor potencial hepatotóxico e hematotóxico, ausência de nefrotoxicidade e, ainda, foi classificado como um xenobiótico de baixa toxicidade após a avaliação da toxicidade aguda. Portanto, o ortobenzamol pode ser considerado como uma futura alternativa terapêutica segura ao paracetamol, no tratamento da dor e inflamação.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

O objetivo do trabalho foi determinar a toxicidade aguda de formalina e os efeitos histopatológicos para o peixe ornamental amazônico corredora bicuda (Corydora melanistius). Foi utilizado um delineamento inteiramente casualizado; com dez concentrações de formalina 40% (0, 3, 6, 12, 25, 50, 100, 150, 200 e 250mg.L-1), com quatro repetições e cinco peixes por recipiente de água (3 L) em sistema estático durante 96 horas. Os peixes moribundos foram mortos e fixados em formol 10% procedendo à análise histopatológica das brânquias e do fígado. Ao final desse experimento, obtiveram-se as seguintes taxas de mortalidades em ordem crescente de exposição (%): 0, 0, 0, 0, 0, 65, 85, 100, 100 e 100. A concentração letal 50% (CL inicial (I)50-96h) foi estimada em 50, 76 mg/L com a seguinte equação de regressão y = 0, 51x com r² = 0, 80. Pode observar nas concentrações mais elevadas, alterações como hiperplasia branquial e fusão lamelar, enquanto que no fígado foi observado desorganização do arranjo cordonal, assim como necrose no rim. Com isso no presente estudo, a formalina pode ser considerada pouco tóxica para a corredora bicuda, mas causa alterações morfológicas acentuadas quando expostas a concentrações elevadas. Dessa forma o uso de formalina no próprio rio de coleta dos peixes com a utilização de dosagens erradas pode causar impactos ambientais e biológicos negativos.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

30.00% 30.00%

Publicador:

Resumo:

OBJECTIVE: The objective of this study was to perform a nutritional assessment of acute kidney injury patients and to identify the relationship between nutritional markers and outcomes.METHOD: This was a prospective and observational study. Patients who were hospitalized at the Hospital of Botucatu School of Medicine were evaluated between January 2009 and December 2011. We evaluated a total of 133 patients with a clinical diagnosis of acute kidney injury and a clinical presentation suggestive of acute tubular necrosis. We explored the associations between clinical, laboratory and nutritional markers and in hospital mortality. Multivariable logistic regression was used to adjust for confounding and selection bias.RESULTS: Non-survivor patients were older (67 +/- 14 vs. 59 +/- 16 years) and exhibited a higher prevalence of sepsis (57.1 vs. 21.4%) and higher Acute Tubular Necrosis-Individual Severity Scores (0.60 +/- 0.22 vs. 0.41 +/- 0.21) than did survivor patients. Based on the multivariable analysis, laboratorial parameters such as blood urea nitrogen and C-reactive protein were associated with a higher risk of death (OR: 1.013, p = 0.0052; OR: 1.050, p = 0.01, respectively), and nutritional parameters such as low calorie intake, higher levels of edema, lower resistance based on bioelectrical impedance analysis and a more negative nitrogen balance were significantly associated with a higher risk of death (OR: 0.950, p = 0.01; OR: 1.138, p = 0.03; OR: 0.995, p = 0.03; OR: 0.934, p = 0.04, respectively).CONCLUSIONS: In acute kidney injury patients, a nutritional assessment seems to identify nutritional markers that are associated with outcome. In this study, a low caloric intake, higher C-reactive protein levels, the presence of edema, a lower resistance measured during a bioelectrical impedance analysis and a lower nitrogen balance were significantly associated with risk of death in acute kidney injury patients.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

This review will focus on long-term outcomes after acute kidney injury (AKI). Surviving AKI patients have a higher late mortality compared with those admitted without AKI. Recent studies have claimed that long-term mortality in patients after AKI varied from 15% to 74% and older age, presence of previous co-morbidities, and the incomplete recovery of renal function have been identified as risk factors for reduced survival. AKI is also associated with progression to chronic kidney (CKD) disease and the decline of renal function at hospital discharge and the number and severity of AKI episodes have been associated with progression to CKD. IN the most studies, recovery of renal function is defined as non-dependence on renal replacement therapy which is probably too simplistic and it is expected in 60-70% of survivors by 90 days. Further studies are needed to explore the long-term prognosis of AKI patients.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Prolonged intermittent renal replacement therapy (PIRRT) has emerged as an alternative to continuous renal replacement therapy in the management of acute kidney injury (AKI) patients. This trial aimed to compare the dialysis complications occurring during different durations of PIRRT sessions in critically ill AKI patients. We included patients older than 18 years with AKI associated with sepsis admitted to the intensive care unit and using noradrenaline doses ranging from 0.3 to 0.7 mu g/kg/min. Patients were divided into two groups randomly: in G1, 6-h sessions were performed, and in G2, 10-h sessions were performed. Seventy-five patients were treated with 195 PIRRT sessions for 18 consecutive months. The prevalence of hypotension, filter clotting, hypokalemia, and hypophosphatemia was 82.6, 25.3, 20, and 10.6%, respectively. G1 was composed of 38 patients treated with 100 sessions, whereas G2 consisted of 37 patients treated with 95 sessions. G1 and G2 were similar in male predominance (65.7 vs. 75.6%, P=0.34), age (63.6 +/- 14 vs. 59.9 +/- 15.5 years, P=0.28) and Sequential Organ Failure Assessment score (SOFA; 13.1 +/- 2.4 vs. 14.2 +/- 3.0, P=0.2). There was no significant difference between the two groups in hypotension (81.5 vs. 83.7%, P=0.8), filter clotting (23.6 vs. 27%, P=0.73), hypokalemia (13.1 vs. 8.1%, P=0.71), and hypophosphatemia (18.4 vs. 21.6%, P=0.72). However, the group treated with sessions of 10h were refractory to clinical measures for hypotension, and dialysis sessions were interrupted more often (9.5 vs. 30.1%, P=0.03). Metabolic control and fluid balance were similar between G1 and G2 (blood urea nitrogen [BUN]: 81 +/- 30 vs. 73 +/- 33mg/dL, P=1.0; delivered Kt/V: 1.09 +/- 0.24 vs. 1.26 +/- 0.26, P=0.09; actual ultrafiltration: 1731 +/- 818 vs. 2332 +/- 947mL, P=0.13) and fluid balance (-731 +/- 125 vs. -652 +/- 141mL, respectively) . In conclusion, intradialysis hypotension was common in AKI patients treated with PIRRT. There was no difference in the prevalence of dialysis complications in patients undergoing different durations of PIRRT.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Acute respiratory distress syndrome is the most severe manifestation of acute lung injury and it is associated with high mortality rate. Despite better understanding of ARDS pathophysiology, its mechanism is still unclear. Mechanical ventilation is the main ARDS supportive treatment. However, mechanical ventilation is a non-physiologic process and complications are associated with its application. Mechanical ventilation may induce lung injury, referred to as ventilator-induced lung injury. Frequently, VILI is related to macroscopic injuries associated with alveolar rupture. The present article is a review of the literature on ventilator-induced lung injury in acute respiratory distress syndrome. Animal and human studies were reviewed. We mainly selected publications in the past 5 years, but did not exclude commonly referenced and highly regarded older publications.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Introduction C-reactive protein (CRP) levels rise during inflammatory processes and have been ordered for rheumatic disease follow-up since the 1950s. The number of tests ordered in the emergency setting has increased, but without evident improvement in medical care quality. Objective To determine the pattern of CRP determinations in the emergency department (ED) of a university hospital in Sao Paulo, Brazil, and to evaluate the effect of an intervention with staff and students about the best use of the test in the ED. Methods Data regarding CRP testing requests, related diagnoses and the number of monthly consultations in the hospital ED were analysed before and after the intervention. Because of an increase in CRP measurement requests from 2007 to 2009, the author started discussing the role of CRP determinations in the medical decision-making process in early 2010. Staff and faculty members openly discussed the pattern of requests in the hospital and related current medical literature. During 2010, the medical staff worked as multipliers to change the behaviour of new students and residents. The results of the first 4 months after the intervention were presented at another general meeting in July 2010. Results From 2007 to 2009, there were 11 786 CRP measurement requests with a clear exponential trend. After the intervention, during the calendar year 2010, there was a 48% reduction in adjusted annual CRP requests. Pneumonia, fever and urinary tract infections were the most common reasons for CRP requests. Discussion Inexpensive, well-directed, interactive educational interventions may affect professional behaviour and curb rates of laboratory tests.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated with chemotherapy only. Whether this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) remains uncertain. Patients and Methods We analyzed 206 patients who underwent HLA-identical sibling and matched unrelated HSCTs reported to the European Group for Blood and Marrow Transplantation with a diagnosis of AML with normal cytogenetics and data on FLT3/ITD (present: n = 120, 58%; absent: n = 86, 42%). Transplantations were performed in first complete remission (CR) after myeloablative conditioning. Results Compared with FLT3/ITD-negative patients, FLT3/ITD-positive patients had higher median leukocyte count at diagnosis (59 v 21 x 10(9)/L; P < .001) and shorter interval from CR to transplantation (87 v 99 days; P = .04). Other characteristics were similar in the two groups. At 2 years, relapse incidence (RI; +/- standard deviation) was higher (30% +/- 5% v 16% +/- 5%; P = .006) and leukemia-free survival (LFS) lower (58% +/- 5% v 71% +/- 6%; P = .04) in FLT3/ITD-positive compared with FLT3/ITD-negative patients. In multivariate analyses, FLT3/ITD led to increased RI (hazard ratio [HR], 3.4; 95% CI, 1.46 to 7.94; P = .005), as did older age, female sex, shorter interval between CR and transplantation, and higher number of chemotherapy courses before achieving CR. FLT3/ITD positivity was associated with decreased LFS (HR, 0.37; 95% CI, 0.19 to 0.73; P = .002), along with older age and higher number of chemotherapy courses before achieving CR. Conclusion FLT3/ITD adversely affected the outcome of HSCT in the same direction it does after chemotherapy; despite this, more than half of the patients harboring this mutation who received transplants were alive and leukemia free at 2 years. To further improve the results, use of FLT3 inhibitors before or after HSCT deserves investigation.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Background and Objectives: Patients who survive acute kidney injury (AKI), especially those with partial renal recovery, present a higher long-term mortality risk. However, there is no consensus on the best time to assess renal function after an episode of acute kidney injury or agreement on the definition of renal recovery. In addition, only limited data regarding predictors of recovery are available. Design, Setting, Participants, & Measurements: From 1984 to 2009, 84 adult survivors of acute kidney injury were followed by the same nephrologist (RCRMA) for a median time of 4.1 years. Patients were seen at least once each year after discharge until end stage renal disease (ESRD) or death. In each consultation serum creatinine was measured and glomerular filtration rate estimated. Renal recovery was defined as a glomerular filtration rate value >= 60 mL/min/1.73 m2. A multiple logistic regression was performed to evaluate factors independently associated with renal recovery. Results: The median length of follow-up was 50 months (30-90 months). All patients had stabilized their glomerular filtration rates by 18 months and 83% of them stabilized earlier: up to 12 months. Renal recovery occurred in 16 patients (19%) at discharge and in 54 (64%) by 18 months. Six patients died and four patients progressed to ESRD during the follow up period. Age (OR 1.09, p < 0.0001) and serum creatinine at hospital discharge (OR 2.48, p = 0.007) were independent factors associated with non renal recovery. The acute kidney injury severity, evaluated by peak serum creatinine and need for dialysis, was not associated with non renal recovery. Conclusions: Renal recovery must be evaluated no earlier than one year after an acute kidney injury episode. Nephrology referral should be considered mainly for older patients and those with elevated serum creatinine at hospital discharge.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Background The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. Methods In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. Results At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P = 0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. Conclusions Among patients with unstable angina or myocardial infarction without ST- segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.)